ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 2, 2009, Pages 347-354

  van Leuven, Sander I ^a   Birjmohun, R S ^a   Franssen, R ^a   Bisoendial, R J ^a   De Kort, H ^a   Levels, J H M ^a   Basser, R L ^b   Meijers, J C M ^a   Kuivenhoven, J A ^a   Kastelein, J J ^a   Stroes, E S ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CSL limited   (Australia)

Author keywords

Atherothrombosis; C reactive protein; Endothelium; High density lipoprotein; inflammation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 PHOSPHATIDYCHOLINE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CYTOKINE RELEASE; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT;

ADULT; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 59049087627     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03175.x     Document Type: Article

References (33)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
3. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
4. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
5. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
6. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 1999; 190: 585-90.
7. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005; 25: 1359-63.
8. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002; 99: 13043-8.
9. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics 2006; 6: 721-30.
10. Schwalbe RA, Coe JE, Nelsestuen GL. Association of rat C-reactive protein and other pentraxins with rat lipoproteins containing apolipoproteins E and A1. Biochemistry 1995; 34: 10432-9.
11. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-64.
12. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-72.
13. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, Rye KA, Barter PJ, Vadas MA, Xia P. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004; 109: 2116-22.
14. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-6.
15. Bisoendial RJ, Kastelein JJ, Peters SL, Levels JH, Birjmohun R, Rotmans JI, Hartman D, Meijers JC, Levi M, Stroes ES. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 2007; 48: 952-60.
16. Lerch PG, Fortsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 1996; 71: 155-64.
17. Olinga P, Merema M, Hof IH, de Jong KP, Slooff MJ, Meijer DK, Groothuis GM. Effect of human liver source on the functionality of isolated hepatocytes and liver slices. Drug Metab Dispos 1998; 26: 5-11.
18. Sprenger RR, Speijer D, Back JW, De Koster CG, Pannekoek H, Horrevoets AJ. Comparative proteomics of human endothelial cell caveolae and rafts using twodimensional gel electrophoresis and mass spectrometry. Electrophoresis 2004; 25: 156-72.
19. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005; 97: e97-103.
20. Olinga P, Merema MT, de Jager MH, Derks F, Melgert BN, Moshage H, Slooff MJ, Meijer DK, Poelstra K, Groothuis GM. Rat liver slices as a tool to study LPS-induced inflammatory response in the liver. J Hepatol 2001; 35: 187-94.
21. Taskinen S, Kovanen PT, Jarva H, Meri S, Pentikainen MO. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 2002; 367: 403-12.
22. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005; 25: 717-22.
23. Masuda M, Miyoshi H, Kobatake S, Nishimura N, Dong XH, Komiyama Y, Takahashi H. Increased soluble FcgammaRIIIa(Mphi) in plasma from patients with coronary artery diseases. Atherosclerosis 2006; 188: 377-83.
24. Barlage S, Boettcher D, Boettcher A, Dada A, Schmitz G. High density lipoprotein modulates platelet function. Cytometry A 2006; 69: 196-9.
25. Diederich W, Orso E, Drobnik W, Schmitz G. Apolipoprotein AI and HDL(3) inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42. Atherosclerosis 2001; 159: 313-24.
26. Wang X, Liao D, Bharadwaj U, Li M, Yao Q, Chen C. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2008; 28: 519-26.
27. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25: 1225-30.
28. Verma S, Devaraj S, Jialal I. C-reactive protein promotes atherothrombosis. Circulation 2006; 113: 2135-50.
29. Bisoendial R, Birjmohun R, Keller T, van Leuven S, Levels H, Levi M, Kastelein J, Stroes E. In vivo effects of C-reactive protein (CRP)-infusion into humans. Circ Res 2005; 97: E115-6.
30. Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: Evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 2007; 48: 509-12.
31. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-21.
32. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35.
33. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007; 297: 1675-82.